Member Info for Grailor

Excellent! Onwards and upwards!

Well done Nick for topping up.

Hi Nick, Thanks and agree, it was a rhetorical question.

Hi Nick, thanks and got it - interim results due on Wednesday!!

Buy, hold or sell?????????

And again today! I have held this share for a couple of years now and still am not sure what is causing the uptick - anyone any ideas?

One last and final appeal before I leave this board. Please, please everyone ignore the guy!!!! It is the only way to get rid of him. You are falling right into his trap, every time and making this board less than pointless!!

Very simple. Please ignore him, do not respond to him and he will, eventually, go away.

We all need to do this otherwise.....

Also agree. Mon, I thought you had him green boxed??? If so, why do you keep responding to him - let it go man as he's doing a real good job on you!!!

Totally agree, please, please ignore him and he will soon get bored and move on.

Got to be honest, you just encourage him by taking his bait and responding. Please everyone just ignore him!!

Share price nicely on the rise! RNS incoming????
ADYOR

Agree with everything that has been said but its still a bit galling to see the slide back into the 30's given the considerable potential still to be realised!!

I am not going to bang on about this but we often submit screening protocols for subsequent studies because they are non-interventional, involve no risk to the subject and enable screening activities to start prior to approval of the main studies. In this case the characterisation study is the first study and will be a distinct and separate protocol from the screening one. The RNS in Feb informed us that the characterisation study had received Ethics approval, it did not state that they had received MHRA approval, which I believe has not yet occurred.
The proof of the pudding is that the characterisation study is not registered in Clintrials.gov and this has to be done prior to starting the study, irrespective of OO issuing an RNS or not.
The idea of them wanting to keep the study under wraps is a bizarre one, given the media coverage to date around this collaboration. Anyway, ADYOR!

Hi Ivy, as you will see from Clitrials.gov, the characterisation study is not registered, only the screening protocol and this does refer to the fact that the 'screened subjects' will potentially be included in the characterisation study when it is approved. So no subjects have been recruited to the actual study, this is just 'screening'.
As I am sure you will agree it would be very odd to put out an RNS confirming ethics approval and then not put out an RNS confirming MHRA approval of a 'first in type' study of such importance.
So just wondering why this is taking so long???

Just wondering why the Covid 19 characterisation study has still not received regulatory approval? Ethics approval was gained over a month ago and the screening protocol was posted on Clintrials.gov on 5th February. No real mention from CF on this either. Any thoughts?

Great chance for another top up!!

So much for my afternoon dip!! Oh well still extremely cheap IMHO!

Will wait for the afternoon dip before my top up!

Magoo - love it!!! ;)

DG - good question! I am wondering if this is why the MHRA approval of the challenge study has been 'delayed'. I actually sent an email to Hvivo a couple of weeks ago asking about the impact of the variants on the development of the challenge study but have yet to receive a reply.
In my view the challenge agent would be one strain of the Covid-19 virus and that they would have to produce new challenge agents if the variants have mutated to a point where a given vaccine would not be effective. In my view the development of the variants has really made the CHIM approach much more 'challenging' ;). ofcourse ADYOR.

My only other thought was around the potential impact of the 'new' Covid variants on the viability and validity of the challenge studies ie. is the Covid challenge agent representative of all strains? Perhaps that has caused some wheel spin with the government funded initiative, Hvivo and thus OO.